Omeros
About Omeros PipelineInvestorsNews
Press Release
View printer-friendly version << Back
Omeros to Webcast Presentation at Canaccord Genuity 30th Annual Growth Conference
Company to Issue Second Quarter Financial Results After Market on August 10th

SEATTLE, Aug 05, 2010 /PRNewswire via COMTEX/ --

Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros, will present at the Canaccord Genuity 30th Annual Growth Conference in Boston, Massachusetts on August 10, 2010 at 10:00 a.m. EDT. The presentation will be webcast. The live or archived webcast can be accessed on the "Events" page of the Company's website at www.omeros.com. In addition, on August 10, 2010, Omeros will issue its second quarter financial results.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including four from its PharmacoSurgery(TM) platform and one from its Addiction program, the most advanced of which is in a Phase 3 clinical program. Omeros may also have the near-term capability, through its GPCR program, to add an unprecedented number of wholly new drug targets to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of antibody and small-molecule preclinical programs targeting inflammation and central nervous system disorders.

SOURCE Omeros Corporation